February 6, 2024
(press release)
–
Evonik has launched Vecollage™ Fortify L, a new vegan collagen for the beauty and personal care market that is identical to collagen in the skin. Vecollage™ Fortify L leverages Evonik’s competencies in biotechnology, collagen, and skin care to meet the demand for vegan collagen for applications such as anti-aging and hydrating creams. By using a system solutions approach that combines an innovative product with expertise in skin biology, Evonik has unveiled the effect of recombinant collagen on the dermis, the middle layer of the skin. The launch of Vecollage™ Fortify L brings Evonik a step closer to generating a platform of non-animal and sustainable collagen. This platform will consist of several types of vegan collagen developed by Evonik and together with partners and will cement the company’s position as a prominent player in biotechnology-based active ingredients. Bioactives form part of a growing portfolio of innovative biosolutions developed by the company’s life sciences division, Nutrition & Care. “The future of skincare is all about biotech-based collagen! Brand owners can now offer consumers sustainably sourced, skin-identical collagen. This true hero ingredient clearly shows how sustainability drives us and collaboration defines us,” said Yann d'Hervé, head of Evonik's Care Solutions business line. Vecollage™ Fortify L was developed in partnership with the company Modern Meadow Inc., which specializes in fermentation-based protein development. It provides dual benefits to fortify collagen in the skin by preventing age-related degradation and stimulating the skin’s own collagen production. For decades, collagen has been a sought-after ingredient in cosmetics and dermatology for its ability to improve firmness, elasticity and hydration in the skin. Traditionally, collagen comes from animal and marine sources, but consumers are increasingly looking for ethical and sustainable alternatives, while brands are concerned about supply security issues. Vecollage™ Fortify L is made using fermentation technology, which addresses these challenges by delivering a vegan collagen produced in a controlled manner with a lower ecological footprint. The Care Solutions business, part of the Nutrition & Care division, specializes in concepts for skin care, sun care, color cosmetics, hair care, skin cleansing, active ingredients, alternative preservation and product stabilization. Evonik’s Nutrition & Care division is home to the company’s biotechnology excellence center which applies fermentation technologies in various high-growth markets. Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow. The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees. In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
